Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Halfmann

Showing results (11-20 of 111) with videos related to

Pageof 12
Sort By:
The Lancet. Microbe|April 27, 2023
Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperaturesYukiko Muramoto, Senye Takahashi, Peter J Halfmann, et al.
Research Square|July 18, 2023
Broad Protection Against Clade 1 Sarbecoviruses After a Single Immunization with Cocktail Spike-Protein-Nanoparticle VaccinePeter J Halfmann, Kathryn Loeffler, Augustine Duffy, et al.
Npj Viruses|April 28, 2025
Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variantPeter J Halfmann, Jeong Soo Lee, Nikki McArthur, et al.
Npj Viruses|February 19, 2026
Immunogenicity and protective efficacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccinesPeter J Halfmann, Jeong Soo Lee, Tong Wang, et al.
Ebiomedicine|June 23, 2023
Transmission and re-infection of Omicron variant XBB.1.5 in hamstersPeter J Halfmann, Ryuta Uraki, Makoto Kuroda, et al.
Biotechnology Progress|June 15, 2026
Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteinsPeter J Halfmann, Augustine Duffy, Alex Wee, et al.
Bioengineering & Translational Medicine|September 30, 2021
Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffoldsPeter J Halfmann, Ana Castro, Kathryn Loeffler, et al.
The Journal of Infectious Diseases|August 10, 2023
An Antiviral Role for TRIM14 in Ebola Virus InfectionMakoto Kuroda, Peter J Halfmann, Larissa B Thackray, et al.
Biorxiv : the Preprint Server for Biology|February 4, 2022
Nasally-delivered interferon-λ protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including OmicronZhenlu Chong, Courtney E Karl, Peter J Halfmann, et al.
Veterinary Pathology|December 29, 2021
Pulmonary lesions induced by SARS-CoV-2 infection in domestic catsOlivia M Patania, Shiho Chiba, Peter J Halfmann, et al.
Pageof 12

Showing results (11-20 of 111) with videos related to

Sort By:
Pageof 12
The Lancet. Microbe|April 27, 2023
Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperaturesYukiko Muramoto, Senye Takahashi, Peter J Halfmann, et al.
Research Square|July 18, 2023
Broad Protection Against Clade 1 Sarbecoviruses After a Single Immunization with Cocktail Spike-Protein-Nanoparticle VaccinePeter J Halfmann, Kathryn Loeffler, Augustine Duffy, et al.
Npj Viruses|April 28, 2025
Potent bivalent nanobody constructs that protect against the SARS-CoV-2 XBB variantPeter J Halfmann, Jeong Soo Lee, Nikki McArthur, et al.
Npj Viruses|February 19, 2026
Immunogenicity and protective efficacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccinesPeter J Halfmann, Jeong Soo Lee, Tong Wang, et al.
Ebiomedicine|June 23, 2023
Transmission and re-infection of Omicron variant XBB.1.5 in hamstersPeter J Halfmann, Ryuta Uraki, Makoto Kuroda, et al.
Biotechnology Progress|June 15, 2026
Characterization and immunogenicity of nanoparticle vaccines displaying embecovirus spike proteinsPeter J Halfmann, Augustine Duffy, Alex Wee, et al.
Bioengineering & Translational Medicine|September 30, 2021
Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffoldsPeter J Halfmann, Ana Castro, Kathryn Loeffler, et al.
The Journal of Infectious Diseases|August 10, 2023
An Antiviral Role for TRIM14 in Ebola Virus InfectionMakoto Kuroda, Peter J Halfmann, Larissa B Thackray, et al.
Biorxiv : the Preprint Server for Biology|February 4, 2022
Nasally-delivered interferon-λ protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including OmicronZhenlu Chong, Courtney E Karl, Peter J Halfmann, et al.
Veterinary Pathology|December 29, 2021
Pulmonary lesions induced by SARS-CoV-2 infection in domestic catsOlivia M Patania, Shiho Chiba, Peter J Halfmann, et al.
Pageof 12